Glucagon-like peptide agonists reduced the risk of dementia in patients with type 2 diabetes
A large-scale study by Swedish scientists with a sample of 88381 people has found that taking glucagon-like peptide-1 agonists is associated with a lower risk of dementia in older people with type 2 diabetes mellitus
24.06.2024